HSV-TK suicide gene therapy (Tulane/Merck Sharp & Dohme)

N/A

Report date: 2024/09/02 17:11:59

Base Information

Drug NameHSV-TK suicide gene therapy (Tulane/Merck Sharp & Dohme)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Induced pluripotent stem cells therapy
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsOvarian Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesTulane UniversityMerck & Co Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMerck Sharp & Dohme CorpTulane University
Active IndicationsN/A
Inactive IndicationsOvarian Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A